Cargando…

Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)

BACKGROUND: Mucopolysaccharidosis (MPS) type III (Sanfilippo syndrome) comprises a group of rare, lysosomal storage diseases caused by the deficiency of one of four enzymes involved in the degradation of heparan sulfate. The clinical hallmark of the disease is severe neurological deterioration leadi...

Descripción completa

Detalles Bibliográficos
Autores principales: Muschol, Nicole M., Pape, Daniel, Kossow, Kai, Ullrich, Kurt, Arash-Kaps, Laila, Hennermann, Julia B., Stücker, Ralf, Breyer, Sandra R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498678/
https://www.ncbi.nlm.nih.gov/pubmed/31046785
http://dx.doi.org/10.1186/s13023-019-1065-x
_version_ 1783415663566520320
author Muschol, Nicole M.
Pape, Daniel
Kossow, Kai
Ullrich, Kurt
Arash-Kaps, Laila
Hennermann, Julia B.
Stücker, Ralf
Breyer, Sandra R.
author_facet Muschol, Nicole M.
Pape, Daniel
Kossow, Kai
Ullrich, Kurt
Arash-Kaps, Laila
Hennermann, Julia B.
Stücker, Ralf
Breyer, Sandra R.
author_sort Muschol, Nicole M.
collection PubMed
description BACKGROUND: Mucopolysaccharidosis (MPS) type III (Sanfilippo syndrome) comprises a group of rare, lysosomal storage diseases caused by the deficiency of one of four enzymes involved in the degradation of heparan sulfate. The clinical hallmark of the disease is severe neurological deterioration leading to dementia and death in the second decade of life. Adult MPS patients are generally of short stature. To date there is no clear description of the physical development of MPS III patients. The aim of this study was to document growth reference data for MPS III patients. We collected growth data of 182 German MPS III patients and were able to develop growth charts for this cohort. Growth curves for height, weight, head circumference, and body mass index were calculated and compared to German reference charts. RESULTS: Birth height, weight and head circumference were within the physiological ranges. Both genders were significantly taller than healthy children at 2 years of age, while only male patients were taller at the age of four. Growth velocity decelerated after the ages of 4.5 and 5 years for female and male patients, respectively. Both genders were significantly shorter than the reference group at the age of 17.5 years. Head circumference was larger compared to healthy matched controls within the first 2 years of life and remained enlarged until physical maturity. CONCLUSION: MPS III is a not yet treatable severe neuro-degenerative disease, developing new therapeutic strategies might change the course of the disease significantly. The present charts contribute to the understanding of the natural history of MPS III. Specific growth charts represent an important tool for families and physicians as the expected height at physical maturity can be estimated and therapeutic effects can be monitored. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-019-1065-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6498678
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64986782019-05-09 Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III) Muschol, Nicole M. Pape, Daniel Kossow, Kai Ullrich, Kurt Arash-Kaps, Laila Hennermann, Julia B. Stücker, Ralf Breyer, Sandra R. Orphanet J Rare Dis Research BACKGROUND: Mucopolysaccharidosis (MPS) type III (Sanfilippo syndrome) comprises a group of rare, lysosomal storage diseases caused by the deficiency of one of four enzymes involved in the degradation of heparan sulfate. The clinical hallmark of the disease is severe neurological deterioration leading to dementia and death in the second decade of life. Adult MPS patients are generally of short stature. To date there is no clear description of the physical development of MPS III patients. The aim of this study was to document growth reference data for MPS III patients. We collected growth data of 182 German MPS III patients and were able to develop growth charts for this cohort. Growth curves for height, weight, head circumference, and body mass index were calculated and compared to German reference charts. RESULTS: Birth height, weight and head circumference were within the physiological ranges. Both genders were significantly taller than healthy children at 2 years of age, while only male patients were taller at the age of four. Growth velocity decelerated after the ages of 4.5 and 5 years for female and male patients, respectively. Both genders were significantly shorter than the reference group at the age of 17.5 years. Head circumference was larger compared to healthy matched controls within the first 2 years of life and remained enlarged until physical maturity. CONCLUSION: MPS III is a not yet treatable severe neuro-degenerative disease, developing new therapeutic strategies might change the course of the disease significantly. The present charts contribute to the understanding of the natural history of MPS III. Specific growth charts represent an important tool for families and physicians as the expected height at physical maturity can be estimated and therapeutic effects can be monitored. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-019-1065-x) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-02 /pmc/articles/PMC6498678/ /pubmed/31046785 http://dx.doi.org/10.1186/s13023-019-1065-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Muschol, Nicole M.
Pape, Daniel
Kossow, Kai
Ullrich, Kurt
Arash-Kaps, Laila
Hennermann, Julia B.
Stücker, Ralf
Breyer, Sandra R.
Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
title Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
title_full Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
title_fullStr Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
title_full_unstemmed Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
title_short Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
title_sort growth charts for patients with sanfilippo syndrome (mucopolysaccharidosis type iii)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498678/
https://www.ncbi.nlm.nih.gov/pubmed/31046785
http://dx.doi.org/10.1186/s13023-019-1065-x
work_keys_str_mv AT muscholnicolem growthchartsforpatientswithsanfilipposyndromemucopolysaccharidosistypeiii
AT papedaniel growthchartsforpatientswithsanfilipposyndromemucopolysaccharidosistypeiii
AT kossowkai growthchartsforpatientswithsanfilipposyndromemucopolysaccharidosistypeiii
AT ullrichkurt growthchartsforpatientswithsanfilipposyndromemucopolysaccharidosistypeiii
AT arashkapslaila growthchartsforpatientswithsanfilipposyndromemucopolysaccharidosistypeiii
AT hennermannjuliab growthchartsforpatientswithsanfilipposyndromemucopolysaccharidosistypeiii
AT stuckerralf growthchartsforpatientswithsanfilipposyndromemucopolysaccharidosistypeiii
AT breyersandrar growthchartsforpatientswithsanfilipposyndromemucopolysaccharidosistypeiii